S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:ACAD

ACADIA Pharmaceuticals - ACAD Stock Forecast, Price & News

$16.40
+0.66 (+4.19%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$15.73
$16.43
50-Day Range
$13.01
$19.51
52-Week Range
$12.24
$28.06
Volume
1.36 million shs
Average Volume
2.01 million shs
Market Capitalization
$2.65 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.29

ACADIA Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
35.9% Upside
$22.29 Price Target
Short Interest
Healthy
6.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of ACADIA Pharmaceuticals in the last 14 days
Based on 39 Articles This Week
Insider Trading
Selling Shares
$11,695 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.36) to ($0.73) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

173rd out of 1,117 stocks

Pharmaceutical Preparations Industry

76th out of 550 stocks

ACAD stock logo

About ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Trading Up 3.3 %

Shares of NASDAQ:ACAD traded up $0.52 during trading hours on Friday, reaching $16.26. The stock had a trading volume of 48,170 shares, compared to its average volume of 1,860,590. The firm has a market cap of $2.63 billion, a price-to-earnings ratio of -12.39 and a beta of 0.71. The business's fifty day moving average price is $15.73 and its two-hundred day moving average price is $20.06. ACADIA Pharmaceuticals has a 52-week low of $12.24 and a 52-week high of $28.06.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Rating) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04. The company had revenue of $134.56 million during the quarter, compared to the consensus estimate of $130.06 million. ACADIA Pharmaceuticals had a negative net margin of 39.93% and a negative return on equity of 41.18%. ACADIA Pharmaceuticals's revenue for the quarter was up 16.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.27) earnings per share. Equities research analysts anticipate that ACADIA Pharmaceuticals will post -1.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ACAD shares. SVB Leerink reduced their target price on ACADIA Pharmaceuticals from $27.00 to $21.00 and set an "outperform" rating on the stock in a report on Tuesday. Cowen reduced their target price on ACADIA Pharmaceuticals from $32.00 to $21.00 and set an "outperform" rating on the stock in a report on Monday. Royal Bank of Canada dropped their price target on ACADIA Pharmaceuticals from $26.00 to $21.00 and set an "outperform" rating for the company in a research report on Tuesday. Jefferies Financial Group lowered ACADIA Pharmaceuticals from a "buy" rating to an "underperform" rating and dropped their price target for the stock from $25.00 to $10.00 in a research report on Tuesday, June 21st. Finally, The Goldman Sachs Group dropped their price target on ACADIA Pharmaceuticals from $20.00 to $15.00 and set a "neutral" rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, ACADIA Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $22.72.

Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Stock News Headlines

One Stock Is All You Need 
Step-by-step guide to trading - and winning - in any market conditions with just ONE stock. Learn More. pixel
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
Where ACADIA Pharmaceuticals Stands With Analysts
Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet
See More Headlines
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Company Calendar

Last Earnings
8/08/2022
Today
8/12/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACAD
Employees
514
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.29
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+35.9%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
18 Analysts

Profitability

Net Income
$-167,870,000.00
Pretax Margin
-39.78%

Debt

Sales & Book Value

Annual Sales
$484.14 million
Book Value
$2.69 per share

Miscellaneous

Free Float
115,838,000
Market Cap
$2.65 billion
Optionable
Optionable
Beta
0.71














ACAD Stock - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View ACAD analyst ratings
or view top-rated stocks.

What is ACADIA Pharmaceuticals' stock price forecast for 2022?

18 brokers have issued 1-year target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price forecasts range from $10.00 to $35.00. On average, they predict the company's stock price to reach $22.29 in the next twelve months. This suggests a possible upside of 37.7% from the stock's current price.
View analysts price targets for ACAD
or view top-rated stocks among Wall Street analysts.

How have ACAD shares performed in 2022?

ACADIA Pharmaceuticals' stock was trading at $23.34 on January 1st, 2022. Since then, ACAD shares have decreased by 30.6% and is now trading at $16.19.
View the best growth stocks for 2022 here
.

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our ACAD earnings forecast
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings results on Monday, August, 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.04. The biopharmaceutical company had revenue of $134.56 million for the quarter, compared to analysts' expectations of $130.06 million. ACADIA Pharmaceuticals had a negative net margin of 39.93% and a negative trailing twelve-month return on equity of 41.18%. The firm's revenue was up 16.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.27) EPS.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $510.00 million-$540.00 million, compared to the consensus revenue estimate of $531.12 million.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (7.66%), Emerald Advisers LLC (0.53%), Pictet Asset Management SA (0.52%), Emerald Mutual Fund Advisers Trust (0.47%), Frontier Capital Management Co. LLC (0.35%) and Rice Hall James & Associates LLC (0.34%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James Kihara, James M Daly, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends
.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $16.19.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $2.62 billion and generates $484.14 million in revenue each year. The biopharmaceutical company earns $-167,870,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

The company employs 514 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.

This page (NASDAQ:ACAD) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.